000			03549nam a22004937a 4500
008			221027s20222022 xxu||||| |||| 00| 0 eng d
022			_a0022-4804
024			_a10.1016/j.jss.2022.08.035 [doi]
024			_aS0022-4804(22)00540-6 [pii]
040			_aOvid MEDLINE(R)
099			_a36182676
245			_aPrognostic Predictors of Mortality in Male Breast Cancer: Outcomes in an Urban Population.
251			_aJournal of Surgical Research. 281:192-199, 2022 Sep 28.
252			_aJ Surg Res. 281:192-199, 2022 Sep 28.
253			_aThe Journal of surgical research
260			_c2022
260			_fFY2023
260			_p2022 Sep 28
265			_saheadofprint
266			_d2022-10-27
520			_aCONCLUSIONS: Advanced age, diabetes mellitus, atrial fibrillation, end-stage renal disease, Eastern Cooperative Oncology Group score of 3, poorly differentiated tumors, and metastatic disease are unfavorable prognostic factors in MBC. Compared to female breast cancer, MBC showed poorer overall survival. Copyright © 2022 Elsevier Inc. All rights reserved.
520			_aINTRODUCTION: Male breast cancer (MBC) accounts for 0.5% to 1% of all breast cancers diagnosed annually. The purpose of this study is to evaluate prognostic factors in MBC.
520			_aMETHODS: We performed a retrospective chart review of patients with MBC between 2010 and 2021. Demographics, comorbidities, cancer characteristics, recurrence, and mortality were collected. Cox proportional hazards regression model was used to determine prognostic factors. A Kaplan-Meier curve was used to plot survival probabilities.
520			_aRESULTS: A total of 47 male patients were identified. The mean age at presentation was 64.1 y. Twenty eight (59.6%) patients were African American and 14 patients (29.8%) were Caucasian. Most patients had invasive ductal carcinoma (89.4%) and presented with T1 or T2 tumors (40.4% and 38.3%, respectively). Three patients (6.4%) had a recurrence and eight patients (17%) died. Using mortality as an end point, age (>= 76.1 y) indicated a hazard ratio (HR) of 1.13 (P = 0.004), diabetes mellitus (HR = 5.45, P = 0.023), atrial fibrillation (HR = 8.0, P = 0.009), end-stage renal disease (HR 6.47, P = 0.023), Eastern Cooperative Oncology Group performance status of 3 (HR = 7.92, P = 0.024), poorly differentiated grade (HR = 7.21, P = 0.033), and metastatic disease (HR = 30.94, P = 0.015) had an increased risk of mortality. Overall survival at 3 y was 79.2%.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Washington Hospital Center
656			_aBreast Oncology Fellowship
656			_aMedStar General Surgery Residency
656			_aMedStar Georgetown University Hospital/MedStar Washington Hospital Center
656			_aPlastic Surgery Residency
656			_aSurgery/Breast Surgery
657			_aJournal Article
700			_aDe La Cruz, Lucy
700			_aDeldar, Romina _bMGUH _cMedStar General Surgery Residency _dMD _eResident PGY 4
700			_aGreenwalt, Ian
700			_aGreige, Nicolas _bMGUH _cPlastic Surgery Residency _dMD _eResident PGY 2
700			_aSogunro, Olutayo _bMWHC _cBreast Oncology Fellowship _dDO _eFellow PGY 6
700			_aSon, Jennifer D
700			_aWehner, Patricia
790			_aDe La Cruz L, Deldar R, Greenwalt I, Greige N, Maini AS, Maini M, Sogunro OA, Son JD, Wehner P
856			_uhttps://dx.doi.org/10.1016/j.jss.2022.08.035 _zhttps://dx.doi.org/10.1016/j.jss.2022.08.035
942			_cART _dArticle
999			_c224 _d224